Amphastar Pharmaceuticals, Inc.

AMPH Healthcare Drug Manufacturers Specialty & Generic

Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 5.44%, EPS grew 4.55%, free cash flow grew 87.6% and total debt was flat, each against the same quarter a year earlier.

25.87 0.55 −2.08%
Market cap
$1.1B
P/E
14.9×
Fwd P/E
14.7×
Dividend yield
—
F-score
6/9
Altman Z
2.54
Beneish M
−2.57
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more TTM periods

723.31 719.89 720.53 730.02
Gross Profit
357.04 356.06 341.13 348.11
Operating Income
149.94 140.40 116.74 114.29
EBT
135.67 123.62 102.81 102.02
Income after Tax
111.63 98.09 79.23 78.55
Net Income Common
111.63 98.09 79.23 78.55
EPS (Diluted)
2.26 2.03 1.66 1.69
Shares (Diluted, Weighted)
49.44 48.48 47.62 46.64
Gross Margin
49.36% 49.46% 47.34% 47.68%
EBIT Margin
20.73% 19.50% 16.20% 15.66%
Net Profit Margin
15.43% 13.63% 11.00% 10.76%
Free Cash Flow Margin
15.33% 16.51% 18.76% 20.94%
EBITDA
208.94 200.45 177.53 174.80
EBIT
149.94 140.40 116.74 114.29

Show all line items

In millions of $ except per-share values · columns are period end dates